Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
NEW YORK , March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS), have been selected for presentation at the
Mar 09, 2020
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma
NEW YORK , March 05, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to umbralisib, the Company’s investigational dual inhibitor of PI3K-delta and CK1-epsilon, for the treatment of
Mar 05, 2020
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results
Conference call to be held today, Tuesday, March 3, 2020 at 8:00 AM ET NEW YORK , March 03, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2019 and recent company developments, along with a
Mar 03, 2020
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business Update
Investor Conference Call to be held Tuesday, March 3, 2020 at 8:00 AM ET NEW YORK , Feb. 28, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday March 3, 2020 at 8:00 AM ET to discuss results for the fourth quarter and
Feb 28, 2020
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications Completion of rolling submission for the MZL/FL NDA expected in 1H20 NEW YORK , Jan. 16, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), a
Jan 16, 2020
TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Thursday, January 16, 2020 at 8:00 AM PT NEW YORK , Jan. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the 38 th Annual J.P.
Jan 10, 2020
Displaying 11 - 16 of 16